Monday, April 22, 2019

GT Biopharma approved for Phase I Clinical Trials



I am always a fan of novel approaches to oncology therapies and GT Biopharma clearly falls within this realm.  Their single-chain tri-specific scFV fusion protein technology is nothing if not novel. 

If you would like to learn more about it, they have a very detailed powerpoint presentation on their website here:
https://www.gtbiopharma.com/news-media/presentations

And now they are bringing this into the clinic:
https://www.gtbiopharma.com/news-media/press-releases/detail/166/gt-biopharma-receives-institutional-review-board-approval

This is great news, because theories are nice, and pre-clinical tox studies are informative, but nothing matters until you get it into patients.  And while most companies are looking at incremental steps forward with the minimum possible risk profile (I'm looking at you companies targeting HER2 with a DM1 payload), some companies are willing to get out there with something truly novel, and be OK with accepting failure for the sake of making a giant leap forward. 

Best of luck in your trials.  We'll be watching for the results.

What do you think?  Are the moonshot based companies interesting, or are they distracting from the incremental and often more successful standard technologies?

No comments:

Post a Comment